BioSapien Extends Its Pre-Series A Round To US$7 Million
The funding round was joined by new investors like Golden Gate Ventures, marking the first deployment of its dedicated MENA Fund.
UAE-based biotech startup BioSapien has extended its pre-Series A funding round to $7 million.
The extension – which comes after a $5.5 million pre-Series A funding round in December led by UAE-based Global Ventures, with further involvement from UK-based Dara Holdings – featured prominent new investors including Golden Gate Ventures, marking the Singapore-based venture capital firm's first deployment through its dedicated MENA fund.
Founded in 2018 by Khatija Ali, the biotech startup's flagship product, MediChip, is a 3D-printed, slow-release drug delivery platform that can be attached to any tissue, offering a targeted treatment method with minimal systemic side effects.
By delivering medication directly to the tumor, MediChip reduces the side effects commonly associated with systemic chemotherapy. Localized delivery also requires smaller doses of medication, while still effectively targeting the tumor. This innovative solution not only delivers precise treatment to the affected area, but also helps improve patient recovery.
The new funds will support BioSapien’s efforts to advance patient-focused oncology solutions, with clinical trials for MediChip set to begin in Abu Dhabi in Q2 2025. Initially targeting colorectal cancer, the startup plans to expand into pancreatic and lung cancers while also exploring treatments for non-cancer conditions, such as hormones and biologics.
In a statement, Khatija Ali, CEO and founder of BioSapien, said, “We are delighted to announce our new investment and are grateful for all the support we have received. The expertise and belief in our vision of our investors comes at a critical juncture as we initiate clinical trials in Abu Dhabi. Together, we are working towards a future where localized cancer treatment becomes the global standard.”
Commenting on the investment, Michael Lints, partner at Golden Gate Ventures MENA, said, “Having met CEO and founder Khatija at Hub71 in Abu Dhabi, we were instantly impressed by her passion and vision. Investing in BioSapien aligns with our commitment to supporting transformative technologies that address significant global challenges. This investment not only supports a groundbreaking technology, but also reinforces the Gulf region’s role as a global leader in healthcare innovation.”
This investment is set to accelerate product development, expand manufacturing capabilities, and attract top talent at BioSapien. It will also fast-track the clinical trials in the UAE, thereby bolstering the country’s growing reputation as a global leader in health innovation.
Pictured on image: Khatija Ali, CEO of BioSapien (center) with members of the investment teams from Goldengate, Global Ventures, and Dara Holding.
